These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 35491768)

  • 1. Volume doubling time and radiomic features predict tumor behavior of screen-detected lung cancers.
    Pérez-Morales J; Lu H; Mu W; Tunali I; Kutuk T; Eschrich SA; Balagurunathan Y; Gillies RJ; Schabath MB
    Cancer Biomark; 2022; 33(4):489-501. PubMed ID: 35491768
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peritumoral and intratumoral radiomic features predict survival outcomes among patients diagnosed in lung cancer screening.
    Pérez-Morales J; Tunali I; Stringfield O; Eschrich SA; Balagurunathan Y; Gillies RJ; Schabath MB
    Sci Rep; 2020 Jun; 10(1):10528. PubMed ID: 32601340
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multi-window CT based Radiomic signatures in differentiating indolent versus aggressive lung cancers in the National Lung Screening Trial: a retrospective study.
    Lu H; Mu W; Balagurunathan Y; Qi J; Abdalah MA; Garcia AL; Ye Z; Gillies RJ; Schabath MB
    Cancer Imaging; 2019 Jun; 19(1):45. PubMed ID: 31253194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimisation of volume-doubling time cutoff for fast-growing lung nodules in CT lung cancer screening reduces false-positive referrals.
    Heuvelmans MA; Oudkerk M; de Bock GH; de Koning HJ; Xie X; van Ooijen PM; Greuter MJ; de Jong PA; Groen HJ; Vliegenthart R
    Eur Radiol; 2013 Jul; 23(7):1836-45. PubMed ID: 23508275
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estimating overdiagnosis in low-dose computed tomography screening for lung cancer: a cohort study.
    Veronesi G; Maisonneuve P; Bellomi M; Rampinelli C; Durli I; Bertolotti R; Spaggiari L
    Ann Intern Med; 2012 Dec; 157(11):776-84. PubMed ID: 23208167
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypoxia-Related Radiomics and Immunotherapy Response: A Multicohort Study of Non-Small Cell Lung Cancer.
    Tunali I; Tan Y; Gray JE; Katsoulakis E; Eschrich SA; Saller J; Aerts HJWL; Boyle T; Qi J; Guvenis A; Gillies RJ; Schabath MB
    JNCI Cancer Spectr; 2021 Aug; 5(4):. PubMed ID: 34409252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Large cell carcinoma of the lung: LDCT features and survival in screen-detected cases.
    Mascalchi M; Puliti D; Cavigli E; Cortés-Ibáñez FO; Picozzi G; Carrozzi L; Gorini G; Delorme S; Zompatori M; Raffaella De Luca G; Diciotti S; Eva Comin C; Alì G; Kaaks R
    Eur J Radiol; 2024 Oct; 179():111679. PubMed ID: 39163805
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined use of positron emission tomography and volume doubling time in lung cancer screening with low-dose CT scanning.
    Ashraf H; Dirksen A; Loft A; Bertelsen AK; Bach KS; Hansen H; Pedersen JH; Mortensen J
    Thorax; 2011 Apr; 66(4):315-9. PubMed ID: 21169285
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differences in Patient Outcomes of Prevalence, Interval, and Screen-Detected Lung Cancers in the CT Arm of the National Lung Screening Trial.
    Schabath MB; Massion PP; Thompson ZJ; Eschrich SA; Balagurunathan Y; Goldof D; Aberle DR; Gillies RJ
    PLoS One; 2016; 11(8):e0159880. PubMed ID: 27509046
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lung cancer screening intervals based on cancer risk.
    Zhang L; Yip R; Jirapatnakul A; Li M; Cai Q; Henschke CI; Yankelevitz DF;
    Lung Cancer; 2020 Nov; 149():113-119. PubMed ID: 33007677
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Volume Doubling Times of Pulmonary Metastases in Patients With Bone and Soft-Tissue Sarcomas: Associations With Subsequent New Metastases and Survival After Metastasectomy.
    Ahn Y; Lee SM; Kim MS; Choi S; Kim S; Do KH; Seo JB
    AJR Am J Roentgenol; 2022 Apr; 218(4):624-632. PubMed ID: 34730372
    [No Abstract]   [Full Text] [Related]  

  • 12. Stability and reproducibility of computed tomography radiomic features extracted from peritumoral regions of lung cancer lesions.
    Tunali I; Hall LO; Napel S; Cherezov D; Guvenis A; Gillies RJ; Schabath MB
    Med Phys; 2019 Nov; 46(11):5075-5085. PubMed ID: 31494946
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lung Cancers Manifesting as Part-Solid Nodules in the National Lung Screening Trial.
    Yip R; Henschke CI; Xu DM; Li K; Jirapatnakul A; Yankelevitz DF
    AJR Am J Roentgenol; 2017 May; 208(5):1011-1021. PubMed ID: 28245151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Can peritumoral radiomics increase the efficiency of the prediction for lymph node metastasis in clinical stage T1 lung adenocarcinoma on CT?
    Wang X; Zhao X; Li Q; Xia W; Peng Z; Zhang R; Li Q; Jian J; Wang W; Tang Y; Liu S; Gao X
    Eur Radiol; 2019 Nov; 29(11):6049-6058. PubMed ID: 30887209
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CT derived radiomic score for predicting the added benefit of adjuvant chemotherapy following surgery in stage I, II resectable non-small cell lung cancer: a retrospective multicohort study for outcome prediction.
    Vaidya P; Bera K; Gupta A; Wang X; Corredor G; Fu P; Beig N; Prasanna P; Patil PD; Velu PD; Rajiah P; Gilkeson R; Feldman MD; Choi H; Velcheti V; Madabhushi A
    Lancet Digit Health; 2020 Mar; 2(3):e116-e128. PubMed ID: 33334576
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of radiomic analysis of iodine overlay maps from dual-energy computed tomography in patients with resectable lung cancer.
    Choe J; Lee SM; Do KH; Lee JB; Lee SM; Lee JG; Seo JB
    Eur Radiol; 2019 Feb; 29(2):915-923. PubMed ID: 30054795
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of Low-Dose Computed Tomography Screening for Primary Lung Cancer on Subsequent Risk of Brain Metastasis.
    Su CC; Wu JT; Neal JW; Popat RA; Kurian AW; Backhus LM; Nagpal S; Leung AN; Wakelee HA; Han SS
    J Thorac Oncol; 2021 Sep; 16(9):1479-1489. PubMed ID: 34091050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor volume doubling time as a potential predictor of prognosis in clinical stage I lung squamous cell carcinoma.
    Nakahashi K; Nakatsuka M; Endo M; Shiono S
    J Thorac Dis; 2023 Jul; 15(7):3849-3859. PubMed ID: 37559608
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Persisting new nodules in incidence rounds of the NELSON CT lung cancer screening study.
    Walter JE; Heuvelmans MA; Ten Haaf K; Vliegenthart R; van der Aalst CM; Yousaf-Khan U; van Ooijen PMA; Nackaerts K; Groen HJM; De Bock GH; de Koning HJ; Oudkerk M
    Thorax; 2019 Mar; 74(3):247-253. PubMed ID: 30591535
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lung cancers diagnosed at annual CT screening: volume doubling times.
    Henschke CI; Yankelevitz DF; Yip R; Reeves AP; Farooqi A; Xu D; Smith JP; Libby DM; Pasmantier MW; Miettinen OS;
    Radiology; 2012 May; 263(2):578-83. PubMed ID: 22454506
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.